Dr. Marchionni is a skilled Bioinformaticist with extensive experience in the analysis and interpretation of genome-wide data. He trained in Medicine at the University of Turin, Italy, and obtained his PhD degree in “Structural and Functional Genomics” at the International School for Advanced Studies (ISAS-SISSA), Trieste, Italy.
During his training, Dr. Marchionni had the chance to collaborate with several research institutes, including the FIRC Institute for Molecular Oncology (IFOM, Milan), the RIKEN Genome Science Laboratory (Tsukuba and Yokohama, Japan) and the National Laboratory of the Italian Interuniversity Consortium for Biotechnologies (LNCIB, Trieste).
In the past, Dr. Marchionni major research activities focused on DNA sequences annotation, and the development of novel methods for gene expression profiling analysis. As a member of the FANTOM Consortium, Dr. Marchionni was also actively involved in the annotation of the mouse transcriptome and in the implementation of the associated database.
During his post-doctoral training Dr. Marchionni joined the group of Dr. Parmigiani, in the Oncology Biostatistics Division at Johns Hopkins, where he developed novel approaches to microarray data annotation and analysis, and prepared a systematic review to assess the evidence that the use of gene expression based assays improves prognostic prediction, treatment choice and health outcomes in women newly diagnosed with early stage breast cancer.
Dr. Marchionni is currently working on several large-scale genomics projects that are poised to generate novel methods of genomic analysis. His current research in particular focuses on knowledge integration across different genomics fields of investigation like gene expression and sequence analysis, as well as on gene expression data comparison across different platforms, laboratories, and species, to uncovering genetic contributions to relevant disease phenotypes, with a specific focus on biomarker discovery. In addition, Dr. Marchionni has a strong interest in BPH, and to that end, he is leading a multidisciplinary research program aimed towards building the molecular understanding of epidemiologically important BPH pathways, through the integration of genomic data analysis and “proof-of-principle” experimental validation in laboratory models.
View all on Pubmed
Marchionni L, Afsari B, Geman D, Leek JT. "A simple and reproducible breast cancer prognostic test". BMC Genomics. 2013 May 17;14:336. doi: 10.1186/1471-2164-14-336. PubMed PMID: 23682826; PubMed Central PMCID: PMC3662649
"Androgen induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008 Dec 4;27(57):7180-91. PMID: 18794802
Schaeffer EM*, Marchionni L*, Huang Z, Simons BW, Blackman A, Yu W, Parmigiani G, and Berman DM. Daniel VC*, Marchionni L*, Hierman JS*, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigani G, Dorsch M, Peacock CD,Watkins DN. "A Primary Xenograft Model of Small Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In-Vitro". Cancer Research, 2009 Apr 15;69(8):3364-73. PMID: 19351829; PMCID: PMC2676849
Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Vermeil HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L. "Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors". Epigenetics. 2013 Sep;8(9):907-20. doi: 10.4161/epi.25574. Epub 2013 Jul 19. PubMed PMID: 23880963; PubMed Central PMCID: PMC3883768
Tomasetti C, Marchionni L, Nowak AM, Parmigiani G and Vogelstein. "Only three driver gene mutations are required for the development of lung and colorectal cancers". Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23. doi: 10.1073/pnas.1421839112. Epub 2014 Dec 22. PubMed PMID: 25535351; PMCID: PMC4291633.